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Pancreatic stellate cells have been investigated mostly for their activation process, supposed to support the development of
pancreatic disease. Few studies have been presented on reversal of the activation process in vitro. Thiazolidinediones (TZDs)
have been used as antidiabetics and have now been reported to exert antiﬁbrotic activity. We tested eﬀects of natural and
synthetic ligands of peroxisome proliferator-activated receptor gamma (PPARγ) on human pancreatic ﬁbroblastoid cells (hPFCs)
in search for speciﬁcity of action. Ciglitazone, as a prototype of TZDs, was shown to have reversible growth inhibitory eﬀects
on human pancreatic ﬁbroblastoid cells/stellate cells. Cells treated with ciglitazone for three days showed enhanced lipid content
and induction of proteins involved in lipid metabolism. Collagen synthesis was reduced in hPFC. Interaction of PPARγ with
DNA binding sites upon ligand binding was shown by gel shift analysis. These ﬁndings point toward a potential for adipocyte
diﬀerentiation in human pancreatic ﬁbroblastoid cells.
1.Introduction
Pancreatic stellate cells (PSCs) are interstitial cells of the
pancreas[1],whichinvitroarerapidlyactivatedanddevelop
the phenotype of myoﬁbroblasts, characterised by enhanced
expression of alpha smooth muscle actin (αSMA). This
development is associated with a loss of lipid storage [2].
Activation of PSC and diﬀerentiation into myoﬁbroblasts in
vitro is assumed to be the process underlying activation of
PSC in vivo, leading to enhanced production of extracellular
matrix, and ultimately, towards ﬁbrosis. Pancreatic ﬁbrosis
is found in chronic pancreatitis (CP), or as a desmoplastic
reaction in pancreatic ductal adenocarcinoma (PDAC). In
rats, deposition and degradation of extracellular matrix is
a highly balanced process that occurs during regeneration
of the pancreas after induction of acute pancreatitis [3].2 International Journal of Cell Biology
Repeated injury most likely leads to impairment of reg-
ulatory mechanisms and thus shifts the balanced process
towards matrix deposition and detection of αSMA-positive
interstitial cells or myoﬁbroblasts [4]. A similar deregulation
could be induced by persistent exposure to toxic agents, such
as organic zinc compounds [5]. Pancreatic ﬁbroblasts, or
stellate cells, are major producers of extracellular matrix, and
thus activation and deregulation of these cells is most likely
the key event in formation of ﬁbrotic deposits. Addressing
the process of activation appears to be a means towards the
treatment of ﬁbrosis.
Thiazolidinediones, antidiabetic drugs, and synthetic
ligands ofperoxisome proliferator-activatedreceptor gamma
(PPARγ) have been shown to inhibit the activation of PSC
in vitro [6], and in animal models, PPARgamma ligands
have been shown to ameliorate the development of chronic
pancreatitis[7,8].PPARγ isanuclearreceptorthatdimerises
with retinoid-X-receptor to bind to DNA of target genes.
PPARγ appears to be a central regulator in lipid metabolism
and adipocyte diﬀerentiation [9]. While PPARγ ligands
have been shown to inhibit culture activation of PSC and
maintain a more quiescent state in freshly isolated cells
[6], overexpression of PPARγ itself in immortalized PSCs
inhibits proliferation and reduces collagen synthesis [10]. In
this study, we describe the ultrastructural morphology of
human pancreatic ﬁbroblastoid cells isolated by outgrowth
from human pancreatic tissue samples in comparison to
rat pancreatic stellate cells. The eﬀect of PPARγ ligands on
human pancreatic ﬁbroblastoid cells in vitro and a potential
for adipogenic diﬀerentiation were investigated.
2.MaterialsandMethods
2.1.Materials. Allchemicalswereofhighestanalyticalpurity
purchased from Sigma, Deisenhofen, Biomol Hamburg, or
Merck, Darmstadt, Germany.
2.2. Animals, Tissue, and Cell Culture. All animal work was
carried out according to the procedural and ethical guide-
linesofthelocalAnimalCareandUseCommittee.PSCswere
isolated from female BN/LEW rats, as described before by
isopycnic density centrifugation [11], and were allowed to
adheretoculturedishesfor3dayspriortofurtherprocessing.
Humanpancreatictissuesampleswerederivedfromdiﬀerent
patients who gave informed consent according to institu-
tional ethical procedures. For explantation of human pan-
creatic tissue, culture dishes were either coated with Matrigel
(Becton Dickinson) at a concentration of 0.5mg/mL, or
rat tail collagen, or left untreated. Pancreatic tissue was cut
into small cubes of roughly 2mm3 and placed into droplets
of heterologous human blood plasma containing EGTA.
Coagulation of plasma was started by adding Thromborel
solution (Dade-Behring, Marburg, Germany) and calcium
solution (10mM), keeping the tissue in a plasma clot in
place.Finally,DMEM(Dulbecco’smodiﬁedEagle’smedium)
supplemented with 10% heat-inactivated horse serum, 20%
FBS (fetal bovine serum (Biochrom, Berlin, Germany)),
10mM HEPES, and antibiotics (Amphotericin B, 10μg/mL
streptomycin, 10U/mL penicillin, and 5μg/mL gentamicin)
was added, and tissue explants were incubated at 37◦Ci na
humid atmosphere under 5% CO2. Medium was changed
every three days. Outgrowing cells were documented using
a Zeiss Axiovert microscope (Carl Zeis Jena, Germany). For
isolation and passage of outgrowing cells, the plasma clots
with remaining tissue were removed, and the cell layer was
trypsinised for 10min at 37◦C .C e l l sw e r ep l a t e dw i t hE C M ,
RTC, or on untreated plates in medium containing 10% FBS.
Transformed HPF-T cells were generated by transfection
with a plasmid containing SV40 large T antigen. Cells were
maintained in culture as described above, using DMEM
supplemented with 10% FBS and 100μg/mL geneticin.
Expression of large T antigen increased lifetime of the
cells but did not stably immortalise them. Spontaneously
immortalized rat pancreatic ﬁbroblastoid cells were cultured
as a stable cell line called PFC1. The cells were derived from
rat pancreas after induction of pancreatitis with cerulein
[12]. Cells were kept in DMEM supplemented with 10% FBS
as described above.
2.3. Cell Proliferation Test. For investigation of proliferation
as a direct measure of viability, cells were plated onto 96-well
plates at a density of 2500 cells per well. After 24 hours of
culture, cells were washed with PBS and switched to serum-
free medium for another 24 hours. Subsequently, cells were
treated with the indicated agents for the indicated times,
and 4h before the end of treatment, MTS reagent (Promega,
Madison, Wis) was added, and colour development was
monitored every 60min up to 4h using a Dynatech MR 5000
plate reader. All measurements were carried out in triplicate
in at least 3 diﬀerent experiments (n ≥ 3). Signiﬁcance was
determined by student’s t-test.
2.4. Oil Red Staining. For morphological investigation, cells
were plated onto glass coverslips with or without extracel-
lular matrix compounds in 12-well plates (Costar, Acton,
Mass). Samples were ﬁxed in 2.5% paraformaldehyde (PFA)
inPBSfor20minatroomtemperature(RT).Oilredstaining
was carried out on PFA-ﬁxed material, for 10min in a
saturated solution of oil red (Polysciences, Warrington, Pa)
in ethanol/acetone, washed in distilled water, counterstained
with hematoxylin (Vector Laboratories, Burlingame, Calif),
and mounted in glycerol gelatine.
2.5. Fluorescence-Activated Cell Sorting (FACS). For ﬂow
cytometry analysis, cells were plated at a density of 200.000
cells per well onto 6-well plates and grown overnight. Cells
were then incubated with serum-free medium for 24h and
subsequently treated as indicated. At the end of incubation,
cells were washed with PBS containing 0.1% sodium azide,
and all supernatants were collected; subsequently cells were
detached by incubation with trypsin solution for 10min,
neutralised by addition of growth medium, and collected by
centrifugation. After another wash in PBS containing azide,
cells were treated for analysis. Lipid content was determined
by nile red staining. Cells resuspended in 1mL of PBS were
incubated for 5min with nile red solubilised in DMSOInternational Journal of Cell Biology 3
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Figure 1: Morphological analysis and comparison of PSC and hPFC. (a) Pancreatic stellate cells after 3 days of adherence ﬁxed with
glutaraldehyde/malachitegreentopreservelipiddroplets.(originalmagniﬁcation:3000x).(b)PSCinstandardﬁxationshowinglayeredlipid
droplets (original magniﬁcation: 3000x). (c) Oil red staining of PSC after 3d in culture (original magniﬁcation: 200x). (d) Oil red staining of
human pancreatic ﬁbroblastoid cells (hPFCs) after 3 passages (original magniﬁcation: 200x). (e)–(h) Electron microscopy analysis of hPFC
in standard ﬁxation after 3 passages. (e) Section of three adjacent cells showing dense cytoskeletal structures at sites of adhesion. Throughout
the cytoplasm, multilamellar vesicles and round layered entities (arrows), can be seen (original magniﬁcation: 3000x). (f) Multilamellar
vesicles at higher magniﬁcation (20000x) show diﬀerent stages of membrane degradation. While some structures show stacked lipid bilayers
(arrow), others contain electron-dense “molten” membrane in addition to fuzzy, lighter material (arrowheads). (g) Picture shows layered
lipid entities next to multivesicular lysosomal/autosomal structures (original magniﬁcation 7000x). (h) High magniﬁcation view (85000x)
of layered entity reveals these structures as nonmembrane-bounded lipid droplet.4 International Journal of Cell Biology
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Figure 2: Lipid content evaluated by nile red binding. The ﬁgure
shows the eﬀect of 72h of ciglitazone treatment on human pan-
creatic ﬁbroblastoid cells (hPFCs, hatched columns), transformed
hPFCs (HPF-T grey columns), and rat PFC1 cells (black columns)
in comparison. Nile red binding to cells was evaluated by ﬂow
cytometryandcalculatedas%ofnilered-positivecells.Ciglitazone-
induced nile red binding in all cells tested, and hPFC showed a
high variation of lipid content in untreated cells with the mean
higher than any other cell line tested, but with P = 0.053, the rise in
lipidcontentwasnotsigniﬁcant.(Depictedaremeansplusstandard
deviation, ∗ signiﬁcant versus untreated, n ≥ 3.)
at a concentration of 1μg/mL in the dark. Analysis was
carried out using a Galaxy Analyser (DAKO, Denmark) and
FlowMax software (DAKO, Denmark) at 488nm wavelength
for excitation with detection ﬁlters for FITC and PE for
nile red [13]. For cell cycle analysis, cells resuspended in
0.5mL PBS-EDTA were ﬁxed by addition of an equal volume
of ethanol and incubated for 30min at room temperature.
After washing with PBS-EDTA, cells were treated for 30min
with RNase A at a concentration of 2μg/mL for 30min.
After another wash with PBS-EDTA, propidium iodide
(10mg/mL) was added, and cells were incubated in the dark
for 15min. Subsequently, cells were analysed as described
above (n ≥ 3). Signiﬁcance was determined by student’s t-
test.
2.6. RNA Isolation and PCR (Polymerase Chain Reaction)
Analysis. RNA isolation was carried out using TriFast
reagent (PeqLab, Germany), according to the manufac-
turer’s protocol. RNA was solubilised in RNase-free water
with RNase inhibitor added and stored at −80◦C. Reverse
transcription of 1μg of RNA was carried out with oligo-
dT priming and SuperScript 2 reverse transcriptase (Invit-
rogen) according to the manufacturer’s protocol, and the
resulting cDNA was stored at −20◦C. For ampliﬁcation,
1μL of cDNA was used. PCR was carried out with Hot-
Star Gold PCR mix (Eurogentech, Belgium), using the
following primer pairs for human RNA: GAPDH (5 -
TGAAGGTCGGAGTCAACGGATTTGGT-3 ,5  -CATGTG-
GGCCATGAGGTCCACCAC-3 ,P P A R γ (5 -AACTGCGGG-
GAAACTTGGGAGATTCTCC-3 ,5  -AATAATAA-GGT-
GGAGATGCAG-GCTCC-3 ), LPL (5 -CTTGGAGATGTG-
GACCGAC-3 ,5  -GTGCCATACAGAGAA-ATCTC-3 ),
FAPB (5 -TTGCTACCAGGCAGGTGGCC-3 ,5  -CCAGTG-
TGGTCTCTT-GCCCG-3 ). Products were resolved on 8%
polyacrylamide-TBE gels, stained with ethidium bromide,
and documented with Polaroid ﬁlm (Kodak).
2.7. Procollagen I Propeptide EIA. For analysis of collagen
synthesis, cells were plated in 6-well plates and incubated
in 1mL of serum-free medium containing either ciglita-
zone at a concentration of 3.3μM, or 15Δ-prostaglandin
J2 at 2.5ng/mL. Incubation was carried out for 24–72h.
Supernatants were collected, and cells were harvested for
determination of protein content. Medium was changed
every 24h, if applicable. Determination of collagen synthesis
(n ≥ 3) was carried out using a procollagen type I C-
peptide (PIP) EIA kit according to the manufacturer’s
protocol (Takara Bio Europe S.A.S., France). The assay is
speciﬁc for human procollagen I propeptide released into
the cellular supernatant upon collagen assembly, thus it
representsadirectmeasureofcollagensynthesis.Signiﬁcance
was determined by student’s t-test.
2.8. Electrophoretic Mobility Shift Assay (EMSA). Isolation of
nuclear extracts was carried out according to Sikora et al.
[14], labelling of probes, incubation, and gel analysis was
done as described before [15]. Nucleotide probes were con-
sensus sequences for RXR and PPARγ consensus sequences
from Santa Cruz (San Jose, Calif) and a sequence of rat
acyl-coenzyme A oxidase (5 -gggaacgtgacctttgtcctggtccc-3 )
containing PPAR-response elements.
2.9. Electron Microscopy. Cells were ﬁxed in situ with either
3% glutaraldehyde (GA) in cacodylate buﬀer at pH 7.2
containing 0.1% malachite green [16]o rw i t h2 . 5 %G Aa n d
2.5% PFA in cacodylate buﬀe rf o ra tl e a s t3 0 m i na t4 ◦C.
Further processing was carried out essentially as described
before [17]. Analysis was carried out using EM109 and EM
902 (Zeiss, Oberkochen, Germany).
3. Results
Human pancreatic ﬁbroblastoid cells (hPFCs) were isolated
by outgrowth from human pancreas tissue explanted into
tissue culture plates similar to rat PFCs, as described
before [12]. For comparison, pancreatic stellate cells (PSCs)
were isolated from rat pancreatic tissue by diﬀerential
centrifugation after tissue digest, as described before [11].
Rat PSCs were ﬁxed after 3 days of adherence using glu-
taraldehyde/malachite green (GAM) for lipid preservation,
as depicted in Figure 1(a), and a standard ﬁxation, seen in
Figure 1(b). Lipid droplets were prominent in PSCs after
3 days in culture. They appeared as mostly round dark,
electron-dense structures without a membrane boundary
and mostly unstructured in GAM ﬁxation (Figure 1(a)).
Conventional ﬁxation revealed a more structured appear-
ance, with a darker outer rim, but still no membraneInternational Journal of Cell Biology 5
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Figure 3: Eﬀects of PPARγ ligands on proliferation. (a) Time course of incubation of hPFC with 3.3μM ciglitazone. Proliferation decreases
signiﬁcantly (∗) over time. Reversibility was tested by washout of drug after 48h and incubation in fresh drug-free medium for further
24h, and the proliferation rate did not signiﬁcantly diﬀer from untreated cells. (b) Time course of incubation of PSC-1 cells with 3.3μM
ciglitazone. Proliferation rates decreased signiﬁcantly (∗) over time. The washout experiment did not show reversibility of ciglitazone-
induced inhibition. (c) Eﬀect of PPARγ ligands on PDGF-stimulated proliferation in hPFC. Cells were incubated for 24h with platelet-
derived growth factor (PDGF) at a concentration of 5ng/mL. One hour after the start of PDGF incubation, ciglitazone (cig, 3.3μM) or 15Δ-
prostaglandinJ2 (PGJ2,5μM)wasadded.PDGFinducedasigniﬁcantgrowthstimulation.Ciglitazonetreatmentdidnotsigniﬁcantlyinhibit
this growth induction, but PGJ2 did. (∗Signiﬁcant versus control, # signiﬁcant versus PDGF stimulation.) (d) Eﬀect of PPARγ ligands on
PDGF-stimulated proliferation in HPF-T cells. Cells were incubated for 24h with platelet-derived growth factor (PDGF) at a concentration
of 5ng/mL. One hour after start of PDGF incubation, ciglitazone (cig, 3.3μM) or 15Δ-prostaglandin J2 (PGJ2, 5μM) was added. PDGF
stimulated proliferation signiﬁcantly, and both ciglitazone and 15Δ-prostaglandin J2 inhibited stimulated growth in transformed HPF-T
cells. (∗Signiﬁcant versus control, #signiﬁcant versus PDGF stimulation, n ≥ 3.)
boundary (Figure 1(b)). Alongside the lipid structures, large,
mostly empty vacuoles were seen throughout the cytoplasm.
Oil red staining of PSCs after 3 days in culture, as depicted
in Figure 1(c), showed large, bright red irregular-shaped
entities throughout the cytoplasm of the cells. Oil red
staining of human pancreatic ﬁbroblastoid cells (hPFCs)
after three passages revealed a quite diﬀerent picture, as seen
in Figure 1(d), and the staining pattern shows small dots,
which are more abundant in some cells, while other cells
arealmostdevoidofoilred-positiveparticles.Ultrastructural
analysis of hPFC did not show prominent lipid droplets,
but multiple multilamellar vesicles and small structured
nonmembrane bounded entities (arrows in Figure 1(e)).
Higher magniﬁcation showed stacks of lipid bilayers within6 International Journal of Cell Biology
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Figure 4: Cell cycle analysis. (a) Cell cycle analysis in hPFC cells after 24h, 48, and 72h of treatment with 3.3μM ciglitazone. The rise in G1
phasecells(black)wassigniﬁcantafter24h(∗)and72h( ∗)comparedtoconcomitantcontrolvalues.Sphaseisdepictedinhatchedcolumns,
and G2/M phase is depicted in grey, n ≥ 3. (b) Cell cycle analysis in PFC1 cells shows a steady rise in G1 phase cells over the time of culture,
no matter if treated or not. At 72h of ciglitazone treatment, the diﬀerence compared to controls was signiﬁcant (∗), as well as compared
to 48h of treatment (n ≥ 3). Vinblastine- (VB-) treatment showed a signiﬁcantly reduced number of G1 cells compared to 72h untreated
controls (◦◦) and 72h ciglitazone treatment (◦), and a high level of G2/M phase cells. These eﬀects were diminished by ciglitazone: G1 phase
cell numbers were not signiﬁcantly diﬀerent from 72h ciglitazone only (#), and G2/M phase accumulation was signiﬁcantly reduced (+).
membrane compartments (arrows in Figure 1(f))a n ds t r u c -
tures with reduced, fuzzy, or “molten-” looking lipid layers
(arrowheadsinFigure 1(f)).Rightnexttoregularmultivesic-
ular structures, nonmembrane-bounded homogenous lipid
structures could be seen (Figure 1(g)), which gave a similar
appearance with darkened outer rim, as seen in rat PSCs.
High-resolution analysis as seen in Figure 1(h) revealed the
amorphous nature of a lipid structure, made up of layers
of diﬀerent electron density, without a deﬁning outer lipid
bilayer, which is a characteristic of lipid droplets.
As seen in oil red staining and at ultrastructural level,
lipid droplets were not uniformly distributed in every cell.
In order to quantitate a large number of cells and investigate
whether lipid storage was a generalised feature, not limited
to single individual cells, we used binding of nile red. Nile
red is a dye with high aﬃnity for lipids and allows for
ﬂow cytometry evaluation. Isolates of hPFC from individual
human pancreatic tissues are inhomogeneous in appearance
and often limited in cell numbers, due to a limited lifetime.
We employed a stable cell line of rat pancreatic ﬁbroblastoid
cells, named PFC1, and transformed human pancreatic
ﬁbroblastoid cells, named HPF-T (see Section 2)f o rc o m -
parison. Cells were treated with ciglitazone, a member of
the thiazolidinedione family of PPARγ ligands to test for
its possible inﬂuence on lipid storage. Figure 2(a) shows
the results of 72h treatment with 3.3μM ciglitazone. PFC1
cells showed a mean content of nile red-positive cells of
about 60% which rose signiﬁcantly by 27% after 3 days
of ciglitazone treatment. The transformed human cells,
HPF-T, showed a signiﬁcant increase of lipid content by
36%. Human PFCs revealed a higher amount of nile red
binding to begin with and showed an increase by about
15% of lipid content, which was not signiﬁcant, though
not surprising, as the cells were derived from individual
isolates.
We then tested for eﬀects of PPARγ ligands on cell
proliferation, using a tetrazolium blue-based assay that
reﬂects mitochondrial activity, which is proportional to cell
numbers. Figure 3 shows results for diﬀerent treatments
on PFC1, hPFC, and HPC-T cells. Cells were incubated
with 3.3μM ciglitazone for 24 to 72h, and hPFC showed
a signiﬁcant decrease in proliferation (Figure 3(a)). To test
for reversibility of this eﬀect, whether it was due to growth
inhibition or cell death, cells were treated for 48h with
ciglitazoneandthenwashedandincubatedwithoutthedrug.
After 24h of chase, cell proliferation increased to numbers
not signiﬁcantly diﬀerent from controls. Spontaneously
immortalized rat cells (PFC1, Figure 3(b)) incubated with
3.3μM ciglitazone also showed signiﬁcant reduction of pro-
liferationbutdid not recoverfrom48hciglitazone treatment
after 24h chase. Further tests were performed on the eﬀectof
PPARγ ligands on PDGF- (platelet-derived growth factor)-
induced proliferation (Figures 3(c) and 3(d)). We tested
not only for the synthetic ligand ciglitazone, but also the
natural ligand 15-Δ-prostaglandin J2 (PGJ2). Treatment of
hPFC with 5ng/mL PDGF for 24h resulted in signiﬁcant
stimulation of proliferation, and incubation of PDGF-
stimulated cells with ciglitazone reduced the stimulating
eﬀect. The reduction of PDGF-stimulated proliferation was
signiﬁcantly more pronounced with the natural ligand 15-Δ-
prostaglandin J2 (Figure 3(c)). For the transformed cell line
HPF-T, the results were similar, with signiﬁcant reduction
of PDGF-stimulated proliferation by synthetic and natural
PPARγ ligands (Figure 3(d)).International Journal of Cell Biology 7
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Figure 5: PCR Analysis of lipid metabolism proteins. PCR analysis
was carried out on two individual isolates of hPFC cells under
control conditions (con) and after 24h, 48h, and 72h ciglita-
zone treatment at 3.3μM ciglitazone for HPF55ECM cells, and
control and 72h ciglitazone at 3.3μM for HPF53RTC cells. For
normalisation, β-actin was ampliﬁed. Fatty acid binding protein
(FABP) showed a steady rise in expression over 24–72h being
highest at 72h. Lipoprotein lipase was induced after 72h of
ciglitazone treatment though mRNA levels showed high variations,
evenundercontrolconditionsbetweenisolates.PPARγ wasinduced
at mRNA level after 24h of treatment and highest after 72h for
both samples tested. PCR analysis shows the diﬀerences between
individual isolates of hPFC, while the general responsiveness
towards ciglitazone treatment was similar, basal expression and
induction values varied.
For further investigation of the antiproliferative eﬀect
of ciglitazone, cell cycle analysis was performed over the
time course of 24 to 72 hours at 3.3μM concentration, as
depicted in Figure 4. Propidium iodide staining for DNA
content showed a signiﬁcant increase of G1 phase cells
after 24h and 72h of treatment in hPFC (Figure 4(a)). In
transformedHPF-Tcells,wefoundahigherrateofapoptosis
duringstandardculture,whichwassigniﬁcantlyenhancedby
ciglitazone treatment after 48h and 72h (data not shown).
P F C 1c e l l sw e r et e s t e da sw e l l( Figure 4(b)) and showed
a constant rise in G1 phase cells from 24h to 72h in
control cells and after ciglitazone treatment. As the increase
in cell numbers in G1 phase was moderate, vinblastine
was employed [18]. Vinblastine induces a cell cycle arrest
in G2/M phase. After 72h of vinblastine treatment, G1
phasecellsweresigniﬁcantlyreducedwhilecellsaccumulated
in G2/M phase. This eﬀect was inhibited by ciglitazone
treatment. The percentage of cells in G1 phase under
combinedtreatmentwithciglitazoneandvinblastinewasnot
signiﬁcantly lower than after ciglitazone only treatment for
72h. Furthermore, cell numbers in G2/M phase were signiﬁ-
cantlylowerunderthecombinedinﬂuenceofvinblastineand
ciglitazone than when treated with vinblastine only. So the
eﬀect of ciglitazone on cell cycle progression was conﬁrmed.
In order to conﬁrm the inﬂuence of ciglitazone on hPFC,
we investigated the gene regulation of proteins involved in
lipid metabolism. Figure 5 shows RT-PCR analysis of fatty
acid binding protein (FABP), lipoprotein lipase (LPL), and
PPARγitselfintwoindividualisolatesofhPFC.Overthetime
course of 24 to 72h, RNA levels of FABP rose continually,
while LPL varied in RNA levels, with a maximum after
72h. PPARγ itself was induced after 24h of ciglitazone
treatment and maintained the higher levels. These ﬁndings
were conﬁrmed, when another isolate was investigated after
72h of ciglitazone treatment. Human samples were derived
from patients with pancreatic cancer. Specimens were taken
from morphologically normal areas of tissue after tumour
resection. All analyses on lipid content and induction of lipid
metabolism were carried out on cells of the same original
isolates.
We further tested for the eﬀect of PPARγ ligands on
collagen synthesis, using an immunoassay for procollagen I
propeptide. During collagen ﬁber assembly, the propeptide
is cleaved and concomitantly released into the cell culture
supernatant and can be assessed by immunological tech-
niques. The assay used was speciﬁc for human procollagen
ICp e p t i d e .Figure 6(a) shows that in hPFCs ciglitazone
and the natural ligand 15Δ-prostaglandin J2 inhibit collagen
synthesis after 24, 48h, and 72h of incubation, expressed as
percent of controls. Apparently, the natural ligand is more
eﬀective than ciglitazone in inhibition of collagen synthesis.
As seen before, this analysis revealed that collagen synthesis
in individual hPFC isolates showed diﬀerences; furthermore,
synthesis varied throughout the investigated time course.
Figure 6(b) gives an example of collagen synthesis and
inhibitionbyPPARγ ligandsforoneindividualisolatenamed
HPF71ECM, from a patient treated for pancreatic cancer.
Figure 6(c) shows the range of collagen synthesis for all
untreated controls of hPFC isolates tested at diﬀerent times
of incubation; in general, collagen synthesis appeared to
be maximal 2d after plating and decreased with ongoing
culture, while the amount of collagen synthesis diﬀered.
Figure 6(d) shows results for the transformed human cell
line HPF-T, expressed as percent of control. Ciglitazone
treatment for 24h signiﬁcantly induced collagen synthesis,
while PGJ2 treatment resulted in signiﬁcant inhibition.
Prolonged treatment with ciglitazone led to inhibition of
collagen synthesis (data not shown).
PPARγ action in gene regulation was further investigated
by DNA binding studies, that is, electrophoretic mobility
shift assays (EMSAs), to conﬁrm ciglitazone-induced activity
in the cells investigated. Figure 7 shows binding of PPARγ
to diﬀerent consensus sequences for the three cell types
investigated in this study. PPARγ binds to DNA as a
heterodimer with retinoid X receptor (RXR), thus we used
probes with RXR binding sites as well as PPARγ consensus
sequencesandperformedsupershiftanalyseswithantibodies
speciﬁc for PPARγ to conﬁrm the presence of the molecule
in the heterodimers. Analysis of an individual hPFC isolate
revealed that PPARγ bound in the absence of ligand, which
is in accord with a corepressor binding in the absence of
PPARγ ligands, which is released upon ligand binding to
the dimer [19]. Incubation with 3.3μM ciglitazone for 1h
induced PPARγ binding to the RXR consensus sequence
(Figure 7(a)). For PFC1 cells, we showed a dose-dependent
increase in PPARγ binding to both probes investigated
(Figure 7(b)). In HPF-T cells, we analysed the eﬀects of
diﬀerent inductors for PPARγ and RXR. Ciglitazone as8 International Journal of Cell Biology
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Figure 6: Analysis of collagen synthesis. (a) Procollagen I propeptide (PIP) secretion of hPFC presented as percent of control after 24, 48,
and 72h of ciglitazone (3.3μM) and PGJ2 (5.0μM) treatment. The reduction of PIP content in culture supernatants was signiﬁcant, except
for 48h PGJ2 (#, n ≥ 3). (b) An example of PIP as ng/mg protein for an individual isolate, representing an individual response towards
treatment, and changes in cellular collagen synthesis over time in culture. (c) Depiction of collagen synthesis in control cells of the individual
isolatesusedinthisanalysisasmean,minimum,andmaximumvalues(n ≥3).(d)Collagensynthesisintransformedcells(HPF-T)after24h
of 3.3μM ciglitazone and 5.0μM PGJ2 treatment expressed as percent of control. Within the ﬁrst 24h, HPF-T cells responded to ciglitazone
by a signiﬁcant induction of collagen synthesis, while the natural ligand inhibited collagen synthesis signiﬁcantly (n ≥ 3).
well as the natural ligand PGJ2 induced PPARγ, while
RXR binding was enhanced by retinoic acid-derivatives
like all-trans retinoic acid (ATRA) and 9-cis-retinoic acid
(9cisRA), the former inducing preferentially retinoic acid
receptor (RAR), while the latter has been shown to induce
retinoid X receptor (Figure 7(c)). Pronounced binding was
found for the RXR consensus sequence after PPARγ ligand
stimulation. Stimulation with 9cisRA appeared more eﬃ-
cient than ATRA. The PPARγ consensus sequence showed
considerably less binding but still revealed similar out-
comes.
4. Discussion
Isolation procedures for pancreatic cells of ﬁbroblast lineage
or characteristics yield diﬀerent cell populations. Pancreatic
stellate cells, mostly isolated from rat pancreas by tissue
digestion and diﬀerential centrifugation [1, 2], produce cells
which show lipid storage, as detected by oil red staining;
these cells are isolated by their buoyant density. Loss of lipid
content would be detrimental to the isolation procedure.
On the other hand, cells isolated by outgrowth from tissue
pieces in cell culture are per se activated, they must migrateInternational Journal of Cell Biology 9
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Figure 7: Gel shift analysis of PPARγ. (a) Electrophoretic mobility shift analyses (EMSAs) in hPFC showed DNA binding of PPARγ
under control conditions, in the absence of ligand and in response to ciglitazone (3.3μM) stimulation using a PPARγ consensus sequence.
Supershift analyses with anti-PPARγ antibodies were included to show the speciﬁcity of PPARγ binding. Binding to a retinoid X receptor
(RXR) consensus sequence was visible without ciglitazone treatment, but more pronounced after ligand binding to PPARγ. Supershift
analysis revealed that PPARγ was present in the complex binding to RXR. (b) Analysis of PPARγ binding in rat PFC1 cells. Two diﬀerent
concentrationsofciglitazonewereusedtoshowinductionofdimerformationandbindingtotheRXRconsensussequence.Aclearinduction
is visible with the PPARγ probe already at the lower concentration. Supershift analysis showed that principally the lower of the two bands
contained PPARγ, while the upper band remained in place. (c) Analysis of PPARγ binding in transformed HPF-T cells. Diﬀerent stimulators
were used for diﬀerentiation purposes. Analysis of stimulation with ciglitazone (3.3μM) was compared to 15Δ-prostaglandin J2 (PGJ2 at
5μM), next to all trans retinoic acid (ATRA) and 9-cis-retinoic acid (9cisRA). The lower PPARγ band was induced probing with RXR by
ciglitazone and PGJ2, but ATRA and 9cisRA inductors for retinoid receptors did not stimulate PPARγ binding to this consensus sequence.
Using the consensus sequence of rat acyl coenzyme A oxidase, the signal was considerably weaker, but still induction of receptor binding was
induced by speciﬁc ligands, while RXR binding to this probe appeared reduced.
to leave their environment, and they undergo cell division
in cell culture prior to being harvested as a passageable
cell population with features of ﬁbroblasts [12]. In this
study, we investigated human pancreatic ﬁbroblast-like cells
isolated by outgrowth, and one of the aims was to analyse
whether these cells have the capability of lipid storage.
Ultrastructural analysis revealed that at the earliest time
point of investigation, there were essentially no lipid droplets
resembling those found in rat pancreatic stellate cells by size
or number. However, there appeared to be a considerable
amount of stacked lipid bilayers concentrated in membrane-
boundedvesicles,whichmightgiverisetosmaller,secondary
lipid storing structures with a distinct layering and without
a containing lipid bilayer membrane. As structures like these
are barely seen in tumour cells or others of epithelial origin,
the potential for lipid storage appears to be inherent in
mesenchymal/ﬁbroblast lineages. It is generally believed that
the activation process for stellate cells goes along with loss of10 International Journal of Cell Biology
lipid content and expression of alpha smooth muscle actin as
a marker. We show here that isolation of a priori activated
cells from diﬀerent individuals with diﬀerent etiology of
disease, leading ultimately to surgical intervention, yields
cells which are heterogeneous in appearance but do respond
to pharmaceutical manipulation in a coordinated manner.
Thiazolidinediones, used as antidiabetics, were shown to
inhibit proliferation and activation of rat PSC [6]a n d
immortalized rat PSC [10] in vitro. Similar results were
found for hepatic stellate cells (HSCs) in vitro [20]; most
of these experiments were carried out on cells for rat origin.
Furthermore animal models for chronic pancreatitis [7]a n d
liver ﬁbrosis [21] did respond to treatment with TZDs,
PPARγ ligands by ameliorated ﬁbrotic responses, though
there is also a report on a mouse model of hepatic ﬁbrosis
that was not responsive towards pioglitazone treatment [22].
So far, little is known about human pancreatic ﬁbroblasts
in vitro. Investigation of PPAR gene expression in human
tissues [23] revealed a maximum of PPARγ 1a n d2
expression in human fat tissue, and to a lower extent in
liver, heart, and muscle. Rats and mice show a similar
prevalenceinPPARγ 2expressioninfattissue,butexpression
levels are far lower than in human tissues, which is even
more evident for PPARγ 1. We found PPARγ mRNA in
hPFC untreated control cells after prolonged time in culture,
readily induced by ciglitazone after 24h, and in rat HSCs,
PPARγ expression went down over time in culture but was
inducible by PGJ2 [24]. However, the most successful model
for induction of adipocyte diﬀerentiation is MDI (isobutyl-
methylxanthine/dexamethasone/insulin) treatment, which
usually lasts for 3 days followed by a more or less extended
culture period which was initially developed for mouse 3T3
L1 cells ([22] and references therein) and was successfully
applied to rat HSC [25]. In HSC, MDI treatment restored
a quiescent phenotype by induction of genes regulating
lipid metabolism, an eﬀect also seen by overexpression of
PPARγ [26]. We report here the induction of FABP and
LPL as representatives of lipid metabolism, as well as PPARγ
mRNA induction after ciglitazone treatment. Furthermore,
we report on DNA binding in heterodimers with retinoid
X receptor, thus ensuring direct involvement of PPARγ in
enhanced lipid content.
However, 72h of treatment might not be suﬃcient
for a full-ﬂedged adipogenic diﬀerentiation in human or
rat pancreatic ﬁbroblastoid cells but clearly points towards
activation of signalling pathways leading to reduced prolif-
eration and enhanced lipid content, similar to induction of
adipogenic diﬀerentiation. In addition, we were able to show
a reduction of collagen synthesis by PPARγ ligands, arguing
for reversibility of the activation process. It is tempting, to
speculate, that a reversal of activation by synthetic PPARγ
ligands might work in humans by promoting the inherent
adipogenic potential of pancreatic interstitial ﬁbroblasts.
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